Johnson & Johnson
-
Johnson & Johnson’s $3 Billion Bet: Halda Therapeutics Acquisition Ushers in Next-Gen Cancer Drug Era
Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05 billion signals a pivotal moment in cancer treatment innovation, spotlighting the promise of RIPTAC™ and targeted protein degradation technologies.
-
J&J Stock Slides After Surprise Spinoff, Earnings Beat Expectations
Johnson & Johnson stock dipped after the pharma giant announced a surprise spinoff of its orthopedics business, even as third-quarter earnings and sales beat analyst expectations.